UW ECHO Dementia November 14, 2025: GLP-1 Therapy and the Brain
Arthi Thirumalai, MD, Associate Professor, UW School of Medicine
Recording [YouTube] Slides [PDF]
Resources:
- Cummings JL, Atri A,Feldman HH, et al. EVOKE and EVOKE+: Design of Two Large-Scale, Double-Blind, Placebo-Controlled, Phase 3 Studies Evaluating Efficacy, Safety, and Tolerability of Semaglutide in Early-Stage Symptomatic Alzheimer's Disease. Alzheimers Res Ther. 2025;17(1):14. Published 2025 Jan 8. doi:10.1186/s13195-024-01666-7
- Ren Q, Zhi L, Liu H. Semaglutide Therapy and Accelerated Sarcopenia in Older Adults withType 2 Diabetes: A 24-Month Retrospective Cohort Study. Drug Des Devel Ther. 2025;19:5645-5652. Published 2025 Jul 3. doi:10.2147/DDDT.S531778
- Monney M, Jornayvaz FR, Gariani K. GLP-1 Receptor Agonists Effect on Cognitive Function in Patients with and without Type 2 Diabetes. Deabetes Mtab. 2023;49(5):101470. doi:10.1016/j.diabet.2023.101470
- Press Release on Oral Semaglutide Phase 3 Topline Data: "The EVOKE and EVOKE+ clinical trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression."